Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants

All common shares and pre-funded warrants in the proposed offering would be sold by Disc rather than existing shareholders.

Rhea-AI Summary

Disc Medicine (IRON) has launched a proposed $350 million underwritten public offering of common stock and pre-funded warrants. Certain investors may choose pre-funded warrants, which allow them to purchase common shares, instead of common stock. Disc also intends to grant underwriters a 30-day option to purchase up to an additional $52.5 million of common stock at the public offering price, less underwriting discounts and commissions.

Disc plans to use net proceeds alongside existing cash and marketable securities for research and clinical development, potential commercialization of bitopertin for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), other pre-commercialization activities, and working capital and general corporate purposes. The offering remains subject to market and other conditions; completion, size and terms are not assured.

4 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.The proposed offering would raise $350 million through company-issued common stock and pre-funded warrants. 16% of market cap
• Minor point. Forward-looking: it has not happened yet and may not happen.The intended underwriter option covers up to $52.5 million in additional common stock over 30 days.
• Minor point. Forward-looking: it has not happened yet and may not happen.Planned proceeds would support research and clinical development of current or additional product candidates.
• Minor point. Forward-looking: it has not happened yet and may not happen.Planned proceeds would support potential bitopertin commercialization for EPP and XLP and other candidates' pre-commercialization activities.

Negative

• Moderate point. Forward-looking: it has not happened yet and may not happen.Proposed issuance of common stock and pre-funded warrants would dilute existing shareholders.

News Explained

At the second-quarter 2026 operating cash-use rate, the proposed gross amount equaled 720.6 days; June 30, 2026 cash and short-term investments equaled 1,477.7 days.

Disc Medicine has commenced a proposed $350 million underwritten offering; it is not completed and remains subject to market and other conditions. If completed, Disc would sell the common shares and pre-funded warrants itself and receive net proceeds; the shares sold and any shares issued upon warrant exercise would increase the share count and reduce existing holders’ percentage ownership.

At the reported second-quarter operating cash-use rate, the proposed gross amount equaled 720.6 days of operating cash use, while cash and short-term investments on June 30, 2026 equaled 1,477.7 days at that same rate. The company says a preliminary prospectus supplement will be filed; the prospectus supplement for the specific offering states its final terms, including size, price, and fees.

Sources and calculations

• Disc Medicine proposed public offering announcement (2026-10-19)
• Pre-funded warrant definition (undated)
• Dilution definition (undated)
• Disc Medicine second-quarter 2026 fundamentals (2026Q2)
• Prospectus supplement purpose (undated)

• Offering gross against the last reported quarterly operating outflow, in days at that rate $350,000,000 / ($44,201,000 / 91) = 720.6 days
• Available liquidity against the last reported quarterly operating outflow, in days at that rate ($98,676,000 + $619,070,000) / ($44,201,000 / 91) = 1477.7 days

Argus 15 min delay 43 alerts

-1.37% vs previous close $77.85 last price 14.7x rel. volume Open Argus

Details

Market Reaction – IRON

$65.63 – $102.75 Day Range

$2.99B Mkt Cap at Last Price

On Oct 19, the day this news came out, the latest delayed price for IRON is 1.37% below the previous close. Our momentum scanner has recorded 43 alerts for this stock so far that day. The latest delayed price is $77.85. Relative volume is exceptionally heavy at 14.7x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Proposed offering: $350 million Underwriters' option: Up to $52.5 million

Proposed offering

$350 million

Commencement of an underwritten offering of common stock and pre-funded warrants

Underwriters' option

Up to $52.5 million

Additional shares at the public offering price; 30-day option

Previous Offering Reports

4 past events · Latest: Oct 21

Same Type 4 events

1. Oct 21

   Offering pricing

   24h Move

   -1.1%

   Disc priced an upsized issuer offering alongside shares sold by a selling stockholder.

2. Oct 20

   Proposed offering

   24h Move

   -3.1%

   Disc proposed an offering combining issuer shares with securities sold by a selling stockholder.

3. Jan 22

   Offering pricing

   24h Move

   -2.6%

   Disc priced an upsized issuer offering of common stock and pre-funded warrants.

4. Jan 21

   Proposed offering

   24h Move

   -3.3%

   Disc proposed an issuer offering of common stock and pre-funded warrants.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pre-funded warrants, underwritten public offering, automatic shelf registration statement, form s-3

4 terms

pre-funded warrants financial

"pre-funded warrants to purchase shares of its common stock"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

underwritten public offering financial

"commencement of an underwritten public offering of $350 million"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

automatic shelf registration statement regulatory

"pursuant to an automatic shelf registration statement on Form S-3"

An automatic shelf registration statement is a pre-approved filing that companies submit to securities regulators, allowing them to sell new shares or bonds quickly and efficiently when needed. It acts like a standing permit, enabling the company to raise money without going through a lengthy approval process each time, which can be helpful for responding promptly to market opportunities or needs. For investors, it provides transparency about the company's ability to raise funds and signals planning flexibility.

form s-3 regulatory

"automatic shelf registration statement on Form S-3"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the commencement of an underwritten public offering of $350 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Disc intends to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be sold by Disc. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Disc intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents, and marketable securities, to fund research and clinical development of Disc's current or additional product candidates, to support the potential commercialization of bitopertin for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and additional pre-commercialization activities for its other product candidates, and the remainder for working capital and other general corporate purposes.

Jefferies, Leerink Partners, Morgan Stanley and Cantor are acting as joint book-running managers for the proposed offering.

The proposed offering is being made pursuant to an automatic shelf registration statement on Form S-3 (No. 333-281359) that was previously filed with the Securities and Exchange Commission (SEC) on August 8, 2024. This proposed offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus related to the proposed offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this proposed offering may also be obtained, when available, by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@jefferies.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, (800) 808-7525 ext. 6105 or by email at syndicate@leerink.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York, 10022, or by email at prospectus@cantor.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

About Disc Medicine

Disc Medicine (NASDAQ: IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements related to Disc's expectations regarding the timing, size and structure of the proposed offering, the anticipated use of proceeds from the offering and the anticipated grant to the underwriters of an option to purchase additional shares. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "seek," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. These risks and uncertainties include fluctuations in Disc's stock price, changes in market conditions, the completion of the public offering on the anticipated terms or at all and other risks identified in our SEC filings, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and in the preliminary prospectus supplement related to the proposed offering we will file with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Media Contact
Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com

Investor Relations Contact
Christina Tartaglia
Precision AQ
christina.tartaglia@precisionaq.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much is Disc Medicine's proposed offering, and what securities would it sell?

Disc Medicine proposes to offer $350 million of common stock and, for investors choosing them instead of shares, pre-funded warrants to purchase common stock. Disc also intends to give underwriters a 30-day option to buy up to an additional $52.5 million of common stock. The offering has not been completed.